Results 21 to 30 of about 18,529 (289)

The effectiveness and safety of antifibrinolytics in patients with acute intracranial haemorrhage: statistical analysis plan for an individual patient data meta-analysis [version 2; referees: 2 approved] [PDF]

open access: yesWellcome Open Research, 2018
Introduction: The Antifibrinolytic Trialists Collaboration aims to increase knowledge about the effectiveness and safety of antifibrinolytic treatment by conducting individual patient data (IPD) meta-analyses of randomised trials.
Katharine Ker   +7 more
doaj   +8 more sources

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage

open access: yesBrain and Spine, 2022
Rebleeding is an important cause of death and disability in people with aneurysmal subarachnoid haemorrhage. Rebleeding is probably related to the dissolution of the blood clot at the site of the aneurysm rupture by natural fibrinolytic activity. This review is an update of previously published Cochrane Reviews.To assess the effects of antifibrinolytic
M. Germans   +6 more
doaj   +5 more sources

Scrub Typhus Combined With Septic Shock Disseminated Intravascular Coagulation and Significant Hyperfibrinolysis: A Case Report and Review of the Literature [PDF]

open access: yesCase Reports in Infectious Diseases
Conclusion: The fibrinolytic system in DIC caused by scrub typhus is excessively active, and antifibrinolytic therapy may benefit such patients. Further research on the distinct coagulation abnormalities in scrub typhus–associated DIC would be highly ...
Dewen Ma   +7 more
doaj   +2 more sources

The effectiveness and safety of antifibrinolytics in patients with acute intracranial haemorrhage: statistical analysis plan for an individual patient data meta-analysis [version 1; referees: 2 approved] [PDF]

open access: goldWellcome Open Research, 2017
Introduction: The Antifibrinolytic Trialists Collaboration aims to increase knowledge about the effectiveness and safety of antifibrinolytic treatment by conducting individual patient data (IPD) meta-analyses of randomised trials.
Katharine Ker   +7 more
doaj   +2 more sources

Efficacy and safety of antifibrinolytic agents in spinal surgery

open access: goldChinese Medical Journal, 2019
Background: Significant blood loss is still one of the most frequent complications in spinal surgery, which often necessitates blood transfusion. Massive perioperative blood loss and blood transfusion can create additional risks.
Yuan Lei   +6 more
openalex   +2 more sources

Lessons From Professor Jan van Gijn [PDF]

open access: yesEur J Neurol
European Journal of Neurology, Volume 32, Issue 7, July 2025.
Elena R. Lebedeva, Charles Warlow
wiley   +2 more sources

Tranexamic Acid in Trauma Management: A Review of Evidence [PDF]

open access: yesJournal of Acute Care Surgery, 2023
Hemorrhage is the leading cause of death in trauma patients and trauma induced coagulopathy (TIC) is a major contributor to bleeding mortality. TIC has a diverse pathophysiology triggered by injury and hypoperfusion, including platelet dysfunction ...
Namryeol Kim
doaj   +1 more source

Effect of Intravenous Tranexamic Acid Administration on Blood Loss during and after Caesarean Delivery: A Randomised Controlled Study [PDF]

open access: yesInternational Journal of Anatomy Radiology and Surgery, 2020
Introduction: India remains a major contributor to maternal deaths in the world. Haemorrhage after delivery (both vaginal & caesarean) is the leading cause. To reduce the haemorrhage, oxytocics are routinely used. In heavy bleeding, blood transfusion
Shyamali Dutta   +2 more
doaj   +1 more source

Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics

open access: yesInternational Journal of Molecular Sciences, 2021
Thrombus formation remains a major cause of morbidity and mortality worldwide. Current antiplatelet and anticoagulant therapies have been effective at reducing vascular events, but at the expense of increased bleeding risk.
N. Pechlivani, K. J. Kearney, R. Ajjan
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy